Skip to content

NICE recommends Duchenne drug Translarna for NHS funding

May 2, 2016

We are delighted to inform you that NICE has recommended funding on the NHS in England for Translarna – the first ever drug to treat an underlying genetic cause of Duchenne muscular dystrophy.

Translarna would treat boys whose Duchenne is caused by a nonsense mutation, who are aged five years and over and who are still able to walk.Click here to read more.